Instructions For Use Figure A (Image 01)
Rivastigmine Patch
Product Images NDC 0378-9072
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 0378-9072). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Instructions For Use Figure B (Image 02)
This text appears to describe possible locations for a medical procedure or examination. The left or right upper arm, left or right side of chest, left or right upper back, and left or right lower back are all mentioned as potential areas of focus. It is possible that this information may be a part of a medical form or questionnaire.*
Instructions For Use Figure C (Image 03)
Instructions For Use Figure D (Image 04)
Protective liners are used to cover the sticky surface of a transdermal system, which is a method of transporting drugs through the skin. This can prevent accidental sticking or contamination, as well as providing additional protection for the transdermal system.*
Instructions For Use Figure E (Image 05)
Rivastigmine Structural Formula (Image 06)
Figure 1: Cross Section Of The Rivastigmine Transdermal System (Image 07)
The text refers to components of a medical device, which include a backing film, an acrylic matrix for the drug product, an adhesive silicone layer for skin contact, and a protective release liner that has raised dimples, which is removed before use.*
Rivastigmine Transdermal System 4.6 mg/24 Hours Carton Label (Image 08)
This is a set of instructions for properly discarding the Rivastigmine Transdermal System patch. The user is directed to remove the old patch and apply a new one every 24 hours. The instructions also include details on how to properly dispose of the patch and to contact Mylan for more information. Each patch contains 4.6mg of the medication Rivastigmine. The product is for transdermal use only and should be kept out of the reach of children.*
Rivastigmine Transdermal System 9.5 mg/24 Hours Carton Label (Image 09)
This text provides instructions for the safe disposal of used Rivastigmine Transdermal System patches. The user is instructed to fold the used patch in half and place it in the original pouch before discarding it safely out of the reach of children. The text also mentions that the product contains 30 systems, each delivering 9.5 mg of rivastigmine, and should be used for transdermal use only. For more information, the user can contact Mylan at the provided phone number.*
Rivastigmine Transdermal System 13.3 mg/24 Hours Carton Label (Image 10)
This text is a set of instructions for safely discarding Rivastigmine Transdermal System patches after use. It includes steps for folding the used patch, putting it in its original pouch and safely discarding it out of reach of children. The text also includes details on the dosage and contents of a single patch, as well as the frequency at which new patches should be applied. For more information, readers are directed to call Mylan at a provided phone number.*
Figure 2: Rivastigmine Plasma Concentrations Following Dermal 24-hour Transdermal System Application (Image 11)
Figure 3: Time Course Of The Change From Baseline In Adas-cog Score For Patients Observed At Each Time Point In Study 1 (Image 12)
Figure 4: Distribution Of Adcs-cgic Scores For Patients Completing Study 1 (Image 13)
Figure 5: Time Course Of The Change From Double-blind Baseline In Adcs-iadl Score For Patients Observed At Each Time Point In Study 2 (Image 14)
Figure 6: Time Course Of The Change From Double-blind Baseline In Adas-cog Score For Patients Observed At Each Time Point In Study 2 (Image 15)
Figure 7: Time Course Of The Change From Baseline In Sib Score For Patients Observed At Each Time Point (modified Full Analysis Set–locf) (Image 16)
Figure 8: Time Course Of The Change From Baseline In Adcs-adl-siv Score For Patients Observed At Each Time Point (modified Full Analysis Set–locf) (Image 17)
Instructions For Use Figure F (Image 18)
Instructions For Use Figure G (Image 19)
Instructions For Use Figure H (Image 20)
The text appears to be a description for disposing of a specific type of transdermal system. It instructs the reader to fold the device and place it in the trash. Additionally, it advises that the sticky sides should be folded together and placed in an empty pouch, which should be kept away from children and pets. It is unclear what the specific transdermal system is or why it needs to be disposed of, but the instructions are clear and concise.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
